Pemphigus Companies
Pemphigus is a group of rare autoimmune diseases that affect the skin and mucous membranes, causing blistering and sores. The treatment of pemphigus typically involves immunosuppressive medications and supportive care.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Top Industry Leaders in the Pemphigus Market
Latest Pemphigus Companies Updates:
Argenx: Their investigational drug necuparanumab (ARGX-113) met its primary endpoint in a Phase 3 trial for pemphigus vulgaris, showing statistically significant improvement in blister severity compared to placebo. This paves the way for potential regulatory approval and market entry.
Viela Bio: Their anti-IL-17A antibody inebilizumab (VIB488) demonstrated positive Phase 2b data for treating pemphigus vulgaris, with significant reductions in blister count and steroid use. They're planning Phase 3 trials to confirm these findings.
Amgen's Saphnelo (rituximab-pvvr) received expanded FDA approval for maintenance treatment of adults with pemphigus vulgaris, offering a longer-term management option.
AstraZeneca's Soliris (eculizumab) gained approval in China for treating adult patients with refractory generalized myasthenia gravis (gMG) and anti-acetylcholine receptor (AChR) antibody positivity. While not directly for Pemphigus, this opens doors for wider access to the complement inhibitor with potential benefits for Pemphigus patients as well.
Sanofi acquired Amunix Pharmaceuticals, gaining access to their IL-17A inhibitor AMX-141, which holds promise for Pemphigus treatment.
UCB and Kiniksa Pharmaceuticals entered into a collaboration to develop and commercialize Kiniksa's investigational anti-GM-CSF antibody KHX242 for treating inflammatory diseases, including Pemphigus.
List of Pemphigus Key companies in the market:
- Novartis Pharmaceuticals
- Hoffmann-La Roche
- Principia Biopharma, Inc
- Argenx
- Sanofi S.A
- Pfizer Inc
- Teligent Inc
- GlaxoSmithKline LLC
- Teva Pharmaceutical Industries.
Pemphigus Market Highlights:
Pemphigus Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
